Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 14, 2020

Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting

GlobeNewswire February 3, 2020

Marinus Provides Business Outlook for 2020

GlobeNewswire January 13, 2020

Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

GlobeNewswire January 7, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 13, 2019

Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 13, 2019

Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

GlobeNewswire December 12, 2019

Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

GlobeNewswire December 11, 2019

Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

GlobeNewswire December 11, 2019

Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

GlobeNewswire December 10, 2019

Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting

GlobeNewswire November 27, 2019

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 8, 2019

Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

GlobeNewswire October 29, 2019

Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting

GlobeNewswire October 17, 2019

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire September 27, 2019

Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

GlobeNewswire September 26, 2019

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire August 23, 2019

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

GlobeNewswire August 8, 2019

Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression

GlobeNewswire July 23, 2019

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

GlobeNewswire June 19, 2019